Summit Trail Advisors LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

Summit Trail Advisors LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 46.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,269 shares of the company’s stock after acquiring an additional 2,961 shares during the period. Summit Trail Advisors LLC’s holdings in Zoetis were worth $1,510,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. State Street Corp boosted its position in shares of Zoetis by 0.5% in the third quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after buying an additional 95,856 shares during the period. Geode Capital Management LLC boosted its position in shares of Zoetis by 1.8% in the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock worth $2,030,813,000 after buying an additional 185,364 shares during the period. Mizuho Securities USA LLC boosted its position in shares of Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after buying an additional 4,829,815 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Zoetis by 5.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock worth $761,221,000 after buying an additional 194,542 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Zoetis by 10.6% in the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after buying an additional 279,092 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ZTS. Morgan Stanley decreased their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Piper Sandler cut their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Finally, UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $214.00.

Zoetis Trading Up 0.2 %

Shares of NYSE ZTS opened at $171.71 on Tuesday. The stock’s 50 day moving average price is $169.26 and its two-hundred day moving average price is $179.21. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The stock has a market capitalization of $77.47 billion, a P/E ratio of 32.28, a PEG ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.